Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is April 28, 2025, covering a share repurchase executed on April 25, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of an existing buyback programme established via a non-discretionary agreement on February 24, 2025.
Key Financial Metrics
- Shares Purchased (April 25, 2025): 824,200 ordinary shares.
- Price Range (GBp): Lowest 1,381.50p; Highest 1,397.00p.
- Volume-Weighted Average Price (GBp): 1,389.77p.
- Total Shares Purchased Since Feb 24, 2025: 33,660,452 ordinary shares.
- Treasury Shares Held: 202,730,755 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,112,510,623 ordinary shares.
- Total Voting Rights: 4,112,510,623.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury shares resulting from the April 25 repurchase. The company has purchased over 33.6 million shares since the commencement of the current buyback agreement on February 24, 2025. No other material changes to financial position or operations are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or management commentary regarding future operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties. These risks are referenced as being described in the "Risk factors" section (pages 277 to 285) of the GSK 2024 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the total remaining authorization under the current buyback programme to assess future repurchase capacity.
- Confirm the impact of the increased treasury share count (202,730,755) on earnings per share (EPS) calculations.
- Review the GSK 2024 Annual Report on Form 20-F (pages 277-285) for detailed risk factors referenced in the cautionary statement.
- Monitor subsequent filings to track the progress of the buyback programme initiated on February 24, 2025.